Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR C797S/del19 (#RDB15491)

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, C797S and deletion in exon 19, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from HCC-827 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
 

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
Remarks
Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
備考
Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15491 pENTER-EGFR C797S/del19 DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pENTER-EGFR C797S/del19 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15491).

Reference section:

Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15491_A7K8p1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: rrnBT1ter_F2 (Pr0531)
Region: rrnB T1 ter, attL1, insert 5'
Sequence file: RDB15491_A7K8a.seq check
>D04925A4_A7K8_2_rrnBT1ter_F2_D04_10_ABI24.ab1
    1 AGACAGGTCT TCCGACTGAG CCTTTCGTTT TATTTGATGC CTGGCAGTTC CCTACTCTCG
   61 CGTTAACGCT AGCATGGATG TTTTCCCAGT CACGACGTTG TAAAACGACG GCCAGTCTTA
  121 AGCTCGGGCC CCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA
  181 TTGATGAGCA ATGCTTTTTT ATAATGCCAA CTTTGTACAA AAAAGCAGGC TCCGCGGCCG
  241 CCCCCTTCAC CATGCGACCC TCCGGGACGG CCGGGGCAGC GCTCCTGGCG CTGCTGGCTG
  301 CGCTCTGCCC GGCGAGTCGG GCTCTGGAGG AAAAGAAAGT TTGCCAAGGC ACGAGTAACA
  361 AGCTCACGCA GTTGGGCACT TTTGAAGATC ATTTTCTCAG CCTCCAGAGG ATGTTCAATA
  421 ACTGTGAGGT GGTCCTTGGG AATTTGGAAA TTACCTATGT GCAGAGGAAT TATGATCTTT
  481 CCTTCTTAAA GACCATCCAG GAGGTGGCTG GTTATGTCCT CATTGCCCTC AACACAGTGG
  541 AGCGAATTCC TTTGGAAAAC CTGCAGATCA TCAGAGGAAA TATGTACTAC GAAAATTCCT
  601 ATGCCTTAGC AGTCTTATCT AACTATGATG CAAATAAAAC CGGACTGAAG GAGCTGCCCA
  661 TGAGAAATTT ACAGGAAATC CTGCATGGCG CCGTGCGGTT CAGCAACAAC CCTGCCCTGT
  721 GCAATGTGGA GAGCATCCAG TGGCGGGACA TAGTCAGCAG TGACTTTCTC AGCAACATGT
  781 CGATGGACTT CCAGAACCAC CTGGGCAGCT GCCAAAAGTG TGATCCAAGC TGTCCCAATG
  841 GGAGCTGCTG GGGTGCAGGA GAGGAGAACT GCCAGAAACT GACCAAAATC ATCTGTGCCC
  901 AGCAGTGCTC CGGGCGCTGC CGTGGCAAGT CCCCCCAGTG ACTGCTGCCA CAACCAGTGT
  961 GCTGCAGCTG CACAGGCCCC CCGGGGAGAG CGACTGCCTG GTCTGCCGCA AATTCCGAGA
 1021 CGAAGCCACG TGCAAGGACA CCTGCCCCCC CCACTCATGC TCTACACCCC CCACCCACGT
1081 ACAGAATTGA TGGTGCACCC GAAGGGCCAA AATAACAGCC TTTTTGGGGG TGTCA
//
Primer: pDONR_R (Pr0071)
Region: attL2, insert 3'
Sequence file: RDB15491_A7K8b.seq check
>D04925A4_A7K8_2_pDONR_R_D08_11_ABI24.ab1
    1 GGGGACGTCA GGGACGCTAT GACCATGTAA TACGACTCAC TATAGGGGAT ATCAGCTGGA
   61 TGGCAAATAA TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA AATTGATAAG
  121 CAATGCTTTC TTATAATGCC AACTTTGTAC AAGAAAGCTG GGTCGGCGCG CCCACCCTTT
  181 CATGCTCCAA TAAATTCACT GCTTTGTGGC GCGACCCTTA GGTATTCTGC ATTTTCAGCT
  241 GTGGAGCCCT TAAAGATGCC ATTTGGCTTG GCTTCCTTGG GAAAGAAGTC CTGCTGGTAG
  301 TCAGGGTTGT CCAGGCTAAT TTGGTGGCTG CCTTTCTGGG CCCAGTGGGC AGGGCTGTCG
  361 AATGTGCTGT TGACACAGGT GGGCTGGACA GTGTTGAGAT ACTCGGGGTT GCCCACTGCA
  421 GTGCTGTGGG GGTCCTGGTA GTGTGGGTCT CTGCTGGGCG CGGGGTTCAG AGGCTGATTG
  481 TGATAGACAG GATTCTGCAC AGAGCCAGCG GGCCTTTTGG GAACGGACTG GTTTATGTAT
  541 TCAGGCACTG GGAGGAAGGT GTCGTCTATG CTGTCCTCAG TCAAGGCGCC TGTGGGGTCT
  601 GAGCTGTATC GCTGCAAGAA GCTGTCTTCC TTGATGGGAC AGCTTTGCAG CCCATTTCTA
  661 TCAATGCAAG CCACGGTGGA ATTGTTGCTG GTTGCACTCA GAGAGCTCAG GAGGGGAGTC
  721 CGTGACGTGG AGGGGCTGCT GAAGAAGCCC TGCTGTGGGA TGAGGTACTC GTCGGCATCC
  781 ACCACGTCGT CCATGTCTTC TTCATCCATC AGGGCACGGT AGAAGTTGGA GTCTGTAGGA
  841 CTTGGCAAAT GCATTCTTTC ATCCCCCTGA ATGACAAGGT AGCGCTGGGG GGTCTCGGGC
  901 CATTTTGGAG AATTCGATGA TCAACTCACG GAACTTTGGG CGACTATCTG CGTCTATCAT
  961 CCAGCACTTG ACCATGATCA TGTAGACATC GATGGTACAT ATGGGTGGCT GAGGAGGCGT
 1021 TTCTCCTTTC TCCAGGATGG GAGGAGATCT CGGCTGGGCA AGGATTCCCG CTCATATGAC
1081 TGGAATTCGA AGATCATCAA CCTCCCCAAA ACCAGT
//
Primer: EGFR-F5 (Pr0313)
Region: insert middle region (C797S, del19)
Sequence file: RDB15491_A7K8c.seq check
>D04925A4_A7K8_2_EGFR-F5_D09_12_ABI24.ab1
    1 ACCTTATCGT CATCGCCACT GGGATGGTGG GGGCCCTCCT CTTGCTGCTG GTGGTGGCCC
   61 TGGGGATCGG CCTCTTCATG CGAAGGCGCC ACATCGTTCG GAAGCGCACG CTGCGGAGGC
  121 TGCTGCAGGA GAGGGAGCTT GTGGAGCCTC TTACACCCAG TGGAGAAGCT CCCAACCAAG
  181 CTCTCTTGAG GATCTTGAAG GAAACTGAAT TCAAAAAGAT CAAAGTGCTG GGCTCCGGTG
  241 CGTTCGGCAC GGTGTATAAG GGACTCTGGA TCCCAGAAGG TGAGAAAGTT AAAATTCCCG
  301 TCGCTATCAA GACATCTCCG AAAGCCAACA AGGAAATCCT CGATGAAGCC TACGTGATGG
  361 CCAGCGTGGA CAACCCCCAC GTGTGCCGCC TGCTGGGCAT CTGCCTCACC TCCACCGTGC
  421 AACTCATCAC GCAGCTCATG CCCTTCGGCT CCCTCCTGGA CTATGTCCGG GAACACAAAG
  481 ACAATATTGG CTCCCAGTAC CTGCTCAACT GGTGTGTGCA GATCGCAAAG GGCATGAACT
  541 ACTTGGAGGA CCGTCGCTTG GTGCACCGCG ACCTGGCAGC CAGGAACGTA CTGGTGAAAA
  601 CACCGCAGCA TGTCAAGATC ACAGATTTTG GGCTGGCCAA ACTGCTGGGT GCGGAAGAGA
  661 AAGAATACCA TGCAGAAGGA GGCAAAGTGC CTATCAAGTG GATGGCATTG GAATCAATTT
  721 TACACAGAAT CTATACCCAC CAGAGTGATG TCTGGAGCTA CGGGGTGACC GTTTGGGAGT
  781 TGATGACCTT TGGATCCAAG CCATATGACG GAATCCCTGC CAGCGAGATC TCCTCCATCC
  841 TGGAGAAAGG AGAACGCCTC CCTCAGCCAC CCATATGTAC CATCGATGTC TACATGATCA
  901 TGGTCAAGTG CTGGATGATA GACGCAGATA GTCGCCCAAA GTTCCGTGAG TTGATCATCG
  961 AATTCTCCAA AATGGCCCGA GACCCCCAGC GCTACCCTTG TCATTCACGG GGGATGAAGA
 1021 TGCATTTGCC AAGTCCTACA GACTCTAACT TTCTACCGTG CCCCTGATCA TGGAAGGAGA
1081 CATGGGACGA ACGTTGGATT GGAATTGGCC GGACG
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083. [link to RRC of NBRP]